肠杆菌和铜绿假单胞菌对生物培南敏感性和盘扩散断点的当前趋势。

IF 1.4 4区医学 Q4 IMMUNOLOGY

Indian Journal of Medical Microbiology Pub Date : 2024-08-02 DOI:10.1016/j.ijmmb.2024.100695

Yamuna Devi Bakthavatchalam , Lydia Jennifer , Fiza Abdullah , Devishree Srinivasan , Ranjan Adhiya , Anand Ashok , Kamini Walia , Dhanalakshmi Solaimalai , Balaji Veeraraghavan

{"title":"肠杆菌和铜绿假单胞菌对生物培南敏感性和盘扩散断点的当前趋势。","authors":"Yamuna Devi Bakthavatchalam , Lydia Jennifer , Fiza Abdullah , Devishree Srinivasan , Ranjan Adhiya , Anand Ashok , Kamini Walia , Dhanalakshmi Solaimalai , Balaji Veeraraghavan","doi":"10.1016/j.ijmmb.2024.100695","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Biapenem has been recently approved by the Drug Controller General of India for the treatment of complicated urinary tract infections (cUTI). However, there are no assessment studies that evaluate the <em>in-vitro</em> activity of biapenem against contemporary ESBL-producing Indian Enterobacterales isolates. To determine the activity of biapenem against contemporary ESBLs and/or OXA-1/ampC producing Enterobacterales and <em>Pseudomonas aeruginosa</em> isolates.</p></div><div><h3>Methodology</h3><p>Isolates were tested for susceptibility to biapenem and its comparators using the broth microdilution method. Presence of ESBLs (SHV, TEM, CTX-M) genes, OXA-1, and <em>amp</em>C genes (ACC, ACT, DHA, CIT/CMY, FOX) using multiplex PCR.</p></div><div><h3>Results</h3><p>Against ESBL with OXA-1 and/or ampC-producing <em>E. coli</em>, ESBL-<em>K. pneumoniae</em>, and cephalosporin-resistant <em>P. aeruginosa</em>, biapenem showed <em>in-vitro</em> activity similar to that of meropenem. Overall, a biapenem disc concentration of 10 μg provided no error rates for testing <em>E. coli, K. pneumoniae,</em> and <em>P. aeruginosa</em> isolates.</p></div><div><h3>Conclusion</h3><p>It is more accurate to test biapenem at a 10 μg disc concentration and apply more stringent disc diffusion breakpoints for interpretation.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100695"},"PeriodicalIF":1.4000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Current trend of biapenem susceptibility and disc diffusion breakpoints in Enterobacterales and Pseudomonas aeruginosa\",\"authors\":\"Yamuna Devi Bakthavatchalam , Lydia Jennifer , Fiza Abdullah , Devishree Srinivasan , Ranjan Adhiya , Anand Ashok , Kamini Walia , Dhanalakshmi Solaimalai , Balaji Veeraraghavan\",\"doi\":\"10.1016/j.ijmmb.2024.100695\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Biapenem has been recently approved by the Drug Controller General of India for the treatment of complicated urinary tract infections (cUTI). However, there are no assessment studies that evaluate the <em>in-vitro</em> activity of biapenem against contemporary ESBL-producing Indian Enterobacterales isolates. To determine the activity of biapenem against contemporary ESBLs and/or OXA-1/ampC producing Enterobacterales and <em>Pseudomonas aeruginosa</em> isolates.</p></div><div><h3>Methodology</h3><p>Isolates were tested for susceptibility to biapenem and its comparators using the broth microdilution method. Presence of ESBLs (SHV, TEM, CTX-M) genes, OXA-1, and <em>amp</em>C genes (ACC, ACT, DHA, CIT/CMY, FOX) using multiplex PCR.</p></div><div><h3>Results</h3><p>Against ESBL with OXA-1 and/or ampC-producing <em>E. coli</em>, ESBL-<em>K. pneumoniae</em>, and cephalosporin-resistant <em>P. aeruginosa</em>, biapenem showed <em>in-vitro</em> activity similar to that of meropenem. Overall, a biapenem disc concentration of 10 μg provided no error rates for testing <em>E. coli, K. pneumoniae,</em> and <em>P. aeruginosa</em> isolates.</p></div><div><h3>Conclusion</h3><p>It is more accurate to test biapenem at a 10 μg disc concentration and apply more stringent disc diffusion breakpoints for interpretation.</p></div>\",\"PeriodicalId\":13284,\"journal\":{\"name\":\"Indian Journal of Medical Microbiology\",\"volume\":\"51 \",\"pages\":\"Article 100695\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Medical Microbiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0255085724001701\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085724001701","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

简介比阿培南最近获得了印度药品管理局的批准，用于治疗复杂性尿路感染（cUTI）。然而，目前还没有评估研究来评价比亚培南对产生 ESBL 的印度肠杆菌分离物的体外活性。目的：确定比亚培南对当代产ESBLs和/或OXA-1/ampC的肠杆菌和铜绿假单胞菌分离物的活性：采用肉汤微量稀释法检测分离菌对比亚培南及其类似物的敏感性。使用多重 PCR 检测 ESBL（SHV、TEM、CTX-M）基因、OXA-1 和 ampC 基因（ACC、ACT、DHA、CIT/CMY、FOX）的存在：结果：对于产 OXA-1 和/或 ampC 的 ESBL 大肠杆菌、ESBL-K 肺炎杆菌和耐头孢菌素的铜绿假单胞菌，比亚培南显示出与美罗培南相似的体外活性。总体而言，在检测大肠杆菌、肺炎双球菌和铜绿假单胞菌分离物时，10 微克的生物培南盘浓度不会产生误差：结论：用 10μg 盘浓度检测生物培南更准确，并采用更严格的盘扩散断点进行解释。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Current trend of biapenem susceptibility and disc diffusion breakpoints in Enterobacterales and Pseudomonas aeruginosa

Introduction

Biapenem has been recently approved by the Drug Controller General of India for the treatment of complicated urinary tract infections (cUTI). However, there are no assessment studies that evaluate the in-vitro activity of biapenem against contemporary ESBL-producing Indian Enterobacterales isolates. To determine the activity of biapenem against contemporary ESBLs and/or OXA-1/ampC producing Enterobacterales and Pseudomonas aeruginosa isolates.

Methodology

Isolates were tested for susceptibility to biapenem and its comparators using the broth microdilution method. Presence of ESBLs (SHV, TEM, CTX-M) genes, OXA-1, and ampC genes (ACC, ACT, DHA, CIT/CMY, FOX) using multiplex PCR.

Results

Against ESBL with OXA-1 and/or ampC-producing E. coli, ESBL-K. pneumoniae, and cephalosporin-resistant P. aeruginosa, biapenem showed in-vitro activity similar to that of meropenem. Overall, a biapenem disc concentration of 10 μg provided no error rates for testing E. coli, K. pneumoniae, and P. aeruginosa isolates.

Conclusion

It is more accurate to test biapenem at a 10 μg disc concentration and apply more stringent disc diffusion breakpoints for interpretation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Medical Microbiology IMMUNOLOGY-

CiteScore

2.20

自引率

0.00%

发文量

154

审稿时长

73 days

期刊介绍： Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study. Review articles, Special Articles or Guest Editorials are accepted on invitation.